Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 715 matching trials from the live ClinicalTrials.gov search.
Conditions
Bronchiectasis, Pulmonary Disease, Chronic Obstructive
Interventions
Placebo to Ciprofloxacin DPI (BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Vero Beach, Florida • Jamaica, New York
Conditions
Cystic Fibrosis
Interventions
VX-445/TEZ/IVA, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
28
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 24 more
Conditions
Cystic Fibrosis
Interventions
Dornase alfa, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
14 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 36 more
Conditions
Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)
Interventions
Molgramostim nebulizer solution, PARI eFlow nebulizer system
Drug · Device
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • New Hyde Park, New York + 2 more
Conditions
Cystic Fibrosis
Interventions
Oral Glucose tolerance test, Whole body protein turnover, IV glucose tolerance test, Indirect Calorimetry, Dual Energy X-ray Absorptiometry (DEXA), Growth Hormone Stimulation Test
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Cystic Fibrosis Pulmonary Exacerbation
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions
ANG003 Dose A, ANG003 Dose B, Creon
Drug
Lead sponsor
Anagram Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 23 more
Conditions
Cystic Fibrosis
Interventions
QR-010, Placebo
Drug
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 8 more
Conditions
Cystic Fibrosis
Interventions
VX-770, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Cincinnati, Ohio • Charlottesville, Virginia • Madison, Wisconsin
Conditions
Cystic Fibrosis, Pseudohypoaldosteronism, Nontuberculous Mycobacterial Infection, Chronic Granulomatous Disease, Primary Ciliary Dyskinesia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cystic Fibrosis
Interventions
LUM/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Months and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 17 more
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
Interventions
NHS7108, Zenpep®
Drug
Lead sponsor
Aimmune Nestlé Health Science US R&D, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Conditions
Cystic Fibrosis
Interventions
Observational
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
12 Years and older
Enrollment
452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 31 more
Conditions
Cystic Fibrosis (CF)
Interventions
SION-719, Placebo-to-match SION-719
Drug
Lead sponsor
Sionna Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Denver, Colorado • Iowa City, Iowa • Baltimore, Maryland + 7 more
Completed No phase listed Observational Accepts healthy volunteers

BioEnergetics and Metabolomics in Cystic Fibrosis

NCT02225899
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Active, not recruiting No phase listed Observational

Pulmonary Vascular Disease in CF

NCT04549077
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Indianapolis, Indiana • Cincinnati, Ohio
Conditions
Cystic Fibrosis
Interventions
Lenabasum 20 mg, Lenabasum 5 mg, Placebo
Drug · Other
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 30 more
Completed Not applicable Interventional Accepts healthy volunteers

Zinc Homeostasis and Kinetics in Children With Cystic Fibrosis (CF)

NCT00104494
Conditions
Cystic Fibrosis
Interventions
Zinc acetate (20mg/d)
Drug
Lead sponsor
Cystic Fibrosis Foundation
Other
Eligibility
8 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cystic Fibrosis
Interventions
Early Intervention
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Pentadecanoic acid (PA) and Triheptadecanoin (THA)
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers

Flaxseed Modulates Inflammation and Oxidative Stress in CF

NCT02014181
Conditions
Cystic Fibrosis, Oxidative Stress, Inflammation
Interventions
finely ground flaxseed powder
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Months to 2 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Cystic Fibrosis
Interventions
SP-101 and doxorubicin Cohort 1, SP-101 and doxorubicin Cohort 2
Combination Product
Lead sponsor
Spirovant Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Kansas City, Kansas • Boston, Massachusetts • New York, New York + 1 more